Get involved

Claim

Opening the claim…

No cancer outcome differs between GLP-1 receptor agonists and placebo after correction in these trials: any malignant neoplasm (risk ratio 1.03, 95% CI 0.97 to 1.09), the thirteen cancers linked to excess body fat (1.09, 0.99 to 1.19) and pancreatic cancer (0.99, 0.75 to 1.32); thyroid cancer is nominally more frequent (67 against 32 participants; 1.61, 1.07 to 2.43; p = 0.023) but not after correction (q = 0.075) or under random effects (1.16, p = 0.46). · sciencejournal.ai